Gluetacs Therapeutics
PrivateLast Round
Series A
May 31, 2024
Total Funding Raised
$20.6M
Company Overview
Gluetacs Therapeutics is a biotechnology company that specializes in the development of small molecule oral protein degraders for the treatment of oncology and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gluetacs Therapeutics Comparables
Compare Gluetacs Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GluBio Therapeutics | 89% | |
| HealZen Therapeutics Co., Ltd. | 88% | |
| Shanghai Leadingtac Pharmaceutical Co., Ltd. | 88% |
Gluetacs Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 31, 2024 |
Gluetacs Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gortune Investment | Series A |
Gluetacs Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Gluetacs Therapeutics's valuation, stock price, and market status.
Is Gluetacs Therapeutics a public or private company?
Gluetacs Therapeutics is a private company.
What is the current stock price of Gluetacs Therapeutics?
Gluetacs Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Gluetacs Therapeutics worth (valuation)?
Valuation information for Gluetacs Therapeutics is not publicly available.
Can I buy Gluetacs Therapeutics stock?
Gluetacs Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Gluetacs Therapeutics's last funding round?
Gluetacs Therapeutics's most recent funding round was Series A on May 31, 2024.
Who are the main investors in Gluetacs Therapeutics?
Key investors in Gluetacs Therapeutics include Gortune Investment.
Will Gluetacs Therapeutics IPO soon?
No public IPO plans have been announced for Gluetacs Therapeutics.
How can I track Gluetacs Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Gluetacs Therapeutics's secondary market activity and sign up for updates.